{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:01:41Z","timestamp":1784811701706,"version":"3.55.0"},"reference-count":153,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L258065"],"award-info":[{"award-number":["L258065"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["T-B-023"],"award-info":[{"award-number":["T-B-023"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejphar.2026.179035","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:24:55Z","timestamp":1779899095000},"page":"179035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting the untargeted: Molecular insights and emerging therapeutic strategies for primary aldosteronism"],"prefix":"10.1016","volume":"1029","author":[{"given":"Hanbo","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixuan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib1","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2026.179035_bib2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev.physiol.62.1.573","article-title":"Structure and regulation of amiloride-sensitive sodium channels","volume":"62","author":"Alvarez de la Rosa","year":"2000","journal-title":"Annu. Rev. Physiol."},{"issue":"16","key":"10.1016\/j.ejphar.2026.179035_bib3","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179035_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41581-023-00753-6","article-title":"Primary aldosteronism: molecular medicine meets public health","volume":"19","author":"Azizan","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2026.179035_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fphys.2020.00141","article-title":"Epithelial Na+ channel (ENaC) formed by one or two subunits forms functional channels that respond to shear force","volume":"11","author":"Baldin","year":"2020","journal-title":"Front. Physiol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179035_bib6","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"19","key":"10.1016\/j.ejphar.2026.179035_bib7","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/CIRCULATIONAHA.115.016759","article-title":"Statin use and adrenal aldosterone production in hypertensive and diabetic subjects","volume":"132","author":"Baudrand","year":"2015","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib8","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/ki.1996.237","article-title":"Diversity and regulation of amiloride-sensitive Na+ channels","volume":"49","author":"Benos","year":"1996","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib9","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/endrev\/bnac034","article-title":"Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia","volume":"44","author":"Bertherat","year":"2023","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib10","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-13-0263","article-title":"Regulation of aldosterone secretion: from physiology to disease","volume":"168","author":"Beuschlein","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ng.2550","article-title":"Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension","volume":"45","author":"Beuschlein","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejphar.2026.179035_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.22203\/eCM.v038a17","article-title":"Dexamethasone: chondroprotective corticosteroid or catabolic killer?","volume":"38","author":"Black","year":"2019","journal-title":"Eur. Cell. Mater."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"issue":"18","key":"10.1016\/j.ejphar.2026.179035_bib14","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/bph.13533","article-title":"The function and regulation of acid-sensing ion channels (ASICs) and the epithelial Na+ channel (ENaC): IUPHAR review 19","volume":"173","author":"Boscardin","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101375","article-title":"Old and new genes in primary aldosteronism","volume":"34","author":"Boulkroun","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ejhf.444","article-title":"Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease","volume":"18","author":"Bramlage","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib17","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/HYPERTENSIONAHA.111.187237","article-title":"Eplerenone use in primary aldosteronism during pregnancy","volume":"59","author":"Cabassi","year":"2012","journal-title":"Hypertension"},{"issue":"18","key":"10.1016\/j.ejphar.2026.179035_bib18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1055\/a-2172-7228","article-title":"Salt and aldosterone - reciprocal and combined effects in preclinical models and humans","volume":"56","author":"Chen","year":"2024","journal-title":"Horm. Metab. Res."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib20","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1073\/pnas.96.5.2514","article-title":"Epithelial sodium channel regulated by aldosterone-induced protein sgk","volume":"96","author":"Chen","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/biomedicines9101397","article-title":"Bilateral adrenal hyperplasia: pathogenesis and treatment","volume":"9","author":"Chevalier","year":"2021","journal-title":"Biomedicines"},{"issue":"6018","key":"10.1016\/j.ejphar.2026.179035_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"issue":"45","key":"10.1016\/j.ejphar.2026.179035_bib23","doi-asserted-by":"crossref","first-page":"28314","DOI":"10.1016\/S0021-9258(18)46930-X","article-title":"The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR)","volume":"269","author":"Clark","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/1043-6618(95)80042-5","article-title":"Pharmacology of competitive inhibitors of HMG-CoA reductase","volume":"31","author":"Corsini","year":"1995","journal-title":"Pharmacol. Res."},{"issue":"29","key":"10.1016\/j.ejphar.2026.179035_bib25","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1523\/JNEUROSCI.1512-06.2006","article-title":"Dihydropyridine receptors and type 1 ryanodine receptors constitute the molecular machinery for voltage-induced Ca2+ release in nerve terminals","volume":"26","author":"De Crescenzo","year":"2006","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.119.14177","article-title":"Genetic, cellular, and molecular heterogeneity in adrenals with aldosterone-producing adenoma","volume":"75","author":"De Sousa","year":"2020","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib28","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1053\/meta.2000.7716a","article-title":"Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia","volume":"49","author":"Dobs","year":"2000","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/1060028020968808","article-title":"Osilodrostat: a novel steroidogenesis inhibitor to treat cushing's disease","volume":"55","author":"Dougherty","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jama.1974.03230180016005","article-title":"Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination","volume":"227","author":"Douglas","year":"1974","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000320387","article-title":"High-salt diet and hypertension: focus on the renin-angiotensin system","volume":"34","author":"Drenjancevic-Peric","year":"2011","journal-title":"Kidney Blood Press. Res."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2165\/00003495-200767090-00005","article-title":"Dihydropyridine calcium channel antagonists in the management of hypertension","volume":"67","author":"Epstein","year":"2007","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4062\/biomolther.2025.022","article-title":"RNA therapeutics: focus on antisense oligonucleotides in the nervous system","volume":"33","author":"Ertural","year":"2025","journal-title":"Biomol Ther (Seoul)"},{"issue":"39","key":"10.1016\/j.ejphar.2026.179035_bib34","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib35","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JME-17-0035","article-title":"Somatic and inherited mutations in primary aldosteronism","volume":"59","author":"Fernandes-Rosa","year":"2017","journal-title":"J. Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib36","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens. Res."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib40","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1096\/fasebj.8.8.8181670","article-title":"Molecular properties of epithelial, amiloride-blockable Na+ channels","volume":"8","author":"Garty","year":"1994","journal-title":"FASEB J."},{"issue":"5476","key":"10.1016\/j.ejphar.2026.179035_bib41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr. Physiol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib42","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqae032","article-title":"Cholesterol availability and adrenal steroidogenesis","volume":"165","author":"Gomez-Sanchez","year":"2024","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179035_bib44","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/HYPERTENSIONAHA.123.20921","article-title":"Primary aldosteronism: spatial multiomics mapping of genotype-dependent heterogeneity and tumor expansion of aldosterone-producing adenomas","volume":"80","author":"Gong","year":"2023","journal-title":"Hypertension"},{"issue":"15","key":"10.1016\/j.ejphar.2026.179035_bib45","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.3390\/cancers13153716","article-title":"Primary aldosteronism: metabolic reprogramming and the pathogenesis of aldosterone-producing adenomas","volume":"13","author":"Gong","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1590\/2175-8239-jbn-3661","article-title":"Inappropriate activity of local renin-angiotensin-aldosterone system during high salt intake: impact on the cardio-renal axis","volume":"40","author":"Gonsalez","year":"2018","journal-title":"J Bras Nefrol"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.1982.9","article-title":"Amiloride in primary hyperaldosteronism","volume":"31","author":"Griffing","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib48","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41392-022-01251-0","article-title":"Aging and aging-related diseases: from molecular mechanisms to interventions and treatments","volume":"7","author":"Guo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1681\/ASN.2014050509","article-title":"Crystalglobulin-induced nephropathy","volume":"26","author":"Gupta","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/febs.13840","article-title":"ASIC and ENaC type sodium channels: conformational states and the structures of the ion selectivity filters","volume":"284","author":"Hanukoglu","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2026.179035_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1001\/jama.1963.03710020039012","article-title":"Triamterene with hydrochlorothiazide in the treatment of hypertension","volume":"186","author":"Heath","year":"1963","journal-title":"JAMA"},{"issue":"13\u201314","key":"10.1016\/j.ejphar.2026.179035_bib52","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S1567-5769(02)00163-7","article-title":"Regulatory effects of salt diet on renal renin-angiotensin-aldosterone, and kallikrein-kinin systems","volume":"2","author":"Hettinger","year":"2002","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib53","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1210\/jc.2013-3495","article-title":"Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas","volume":"99","author":"Howard","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib55","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.123.066389","article-title":"Subclinical primary aldosteronism and cardiovascular health: a population-based cohort study","volume":"149","author":"Hundemer","year":"2024","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ejphar.2026.179035_bib57","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMe2031382","article-title":"Finerenone - halting relative hyperaldosteronism in chronic kidney disease","volume":"383","author":"Ingelfinger","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5519","key":"10.1016\/j.ejphar.2026.179035_bib58","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2026.179035_bib59","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.mce.2017.08.019","article-title":"Aberrant G protein-receptor expression is associated with DNA methylation in aldosterone-producing adenoma","volume":"461","author":"Itcho","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib61","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib62","doi-asserted-by":"crossref","first-page":"F377","DOI":"10.1152\/ajprenal.00143.2002","article-title":"Concerted action of ENaC, Nedd4-2, and Sgk1 in transepithelial Na+ transport","volume":"283","author":"Kamynina","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib64","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/jdi.13332","article-title":"Impact of primary aldosteronism on renal function in patients with type 2 diabetes","volume":"12","author":"Katsuragawa","year":"2021","journal-title":"J. Diabetes Investig."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib65","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000518165","article-title":"Laparoscopic adrenalectomy is beneficial for the health-related quality of life of older patients with primary aldosteronism","volume":"107","author":"Kawasaki","year":"2023","journal-title":"Urol. Int."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib66","doi-asserted-by":"crossref","first-page":"F1279","DOI":"10.1152\/ajprenal.00094.2003","article-title":"Characterization of an amiloride binding region in the alpha-subunit of ENaC","volume":"285","author":"Kelly","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib67","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1186\/s12888-023-05275-w","article-title":"Agoraphobia and panic attacks complicated by primary aldosteronism improved by treatment with eplerenone: a case report","volume":"23","author":"Kijima","year":"2023","journal-title":"BMC Psychiatry"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179035_bib68","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s11886-023-01998-0","article-title":"Cardiovascular and renal benefit of novel non-steroidal mineralocorticoid antagonists in patients with dsiabetes","volume":"25","author":"Kintscher","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"issue":"13","key":"10.1016\/j.ejphar.2026.179035_bib69","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib70","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib71","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/HYPERTENSIONAHA.123.20953","article-title":"Hypertension in primary aldosteronism is initiated by salt-induced increases in vascular resistance with reductions in cardiac output","volume":"80","author":"Kurtz","year":"2023","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179035_bib72","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with Lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179035_bib73","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1093\/nar\/gkac483","article-title":"ARMC5 is part of an RPB1-specific ubiquitin ligase implicated in adrenal hyperplasia","volume":"50","author":"Lao","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib74","first-page":"CD012039","article-title":"Pharmacotherapy for hypertension-induced left ventricular hypertrophy","volume":"10","author":"Leache","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.179035_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105332","article-title":"Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data","volume":"163","author":"Lenzini","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib76","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1210\/me.2007-0417","article-title":"Silencing of the mineralocorticoid receptor by ribonucleic acid interference in transgenic rats disrupts endocrine homeostasis","volume":"22","author":"Lim","year":"2008","journal-title":"Mol. Endocrinol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib77","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s40618-025-02594-5","article-title":"Comparative analysis of cardiac dysfunction in non-functioning adrenal adenomas, primary aldosteronism, and essential hypertension","volume":"48","author":"Liu","year":"2025","journal-title":"J. Endocrinol. Investig."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib78","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1021\/acsbiomaterials.2c00026","article-title":"Dexamethasone: insights into pharmacological aspects, therapeutic mechanisms, and delivery systems","volume":"8","author":"Madamsetty","year":"2022","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"22","key":"10.1016\/j.ejphar.2026.179035_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213821","article-title":"Spontaneous remission of primary aldosteronism with mineralocorticoid receptor antagonist therapy: a review","volume":"23","author":"Mai","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.ejphar.2026.179035_bib80","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cells14141114","article-title":"Therapeutic potential of calcium channel blockers in neuropsychiatric, endocrine and pain disorders","volume":"14","author":"Manzar","year":"2025","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib81","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1161\/HYPERTENSIONAHA.125.25104","article-title":"Adrenalectomy versus medical therapy in primary aldosteronism: a meta-analysis of long-term cardiac remodeling and function: medical versus adrenalectomy treatment compared in hyperaldosteronism (MATCH) study","volume":"82","author":"Marzano","year":"2025","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2026.179035_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1254221","article-title":"Statin treatment is not associated with an increased risk of adrenal insufficiency in real-world setting","volume":"14","author":"Maumus-Robert","year":"2023","journal-title":"Front. Endocrinol."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib83","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/00004872-200409000-00002","article-title":"Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences","volume":"22","author":"Meredith","year":"2004","journal-title":"J. Hypertens."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib84","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr. Pathol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib85","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib87","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3390\/nu13030875","article-title":"Unravelling the genetic basis of primary aldosteronism","volume":"13","author":"Mourtzi","year":"2021","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.ejphar.2026.179035_bib88","doi-asserted-by":"crossref","first-page":"e2320","DOI":"10.1210\/clinem\/dgaa206","article-title":"Primary aldosteronism in the elderly","volume":"105","author":"Mulatero","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib89","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/bcp.15713","article-title":"CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers","volume":"89","author":"Mulatero","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib90","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/jhh.2015.98","article-title":"ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions","volume":"30","author":"Mulatero","year":"2016","journal-title":"J. Hum. Hypertens."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib91","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/01.HYP.35.3.694","article-title":"CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism","volume":"35","author":"Mulatero","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2026.179035_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102576","article-title":"Safety and efficacy of once-daily dexfadrostat phosphate in patients with primary aldosteronism: a randomised, parallel group, multicentre, phase 2 trial","volume":"71","author":"Mulatero","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib93","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/HYPERTENSIONAHA.123.21446","article-title":"Single-nucleus analysis reveals tumor heterogeneity of aldosterone-producing adenoma","volume":"81","author":"Murakami","year":"2024","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib94","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bjs.9744","article-title":"Systematic review of surgery and outcomes in patients with primary aldosteronism","volume":"102","author":"Muth","year":"2015","journal-title":"Br. J. Surg."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib95","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1210\/clinem\/dgac408","article-title":"Histopathology and genetic causes of primary aldosteronism in young adults","volume":"107","author":"Nanba","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib96","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1161\/HYPERTENSIONAHA.118.12070","article-title":"Genetic characteristics of aldosterone-producing adenomas in blacks","volume":"73","author":"Nanba","year":"2019","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib97","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.117.10391","article-title":"Aging and adrenal aldosterone production","volume":"71","author":"Nanba","year":"2018","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib98","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib99","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/HYPERTENSIONAHA.118.11086","article-title":"Cellular and genetic causes of idiopathic hyperaldosteronism","volume":"72","author":"Omata","year":"2018","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179035_bib100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1055\/s-0043-122394","article-title":"Aldosterone-producing cell clusters in normal and pathological states","volume":"49","author":"Omata","year":"2017","journal-title":"Horm. Metab. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib101","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.3390\/ijms24065370","article-title":"The effect of aldosterone on cardiorenal and metabolic systems","volume":"24","author":"Otsuka","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib102","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J. Hypertens."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib103","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/hy1101.095010","article-title":"Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects","volume":"38","author":"Pratt","year":"2001","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib104","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1093\/ejendo\/lvad020","article-title":"Mineralocorticoid receptor antagonists for primary aldosteronism-appropriate or not?","volume":"188","author":"Ragnarsson","year":"2023","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179035_bib105","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","article-title":"Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension","volume":"42","author":"Rakugi","year":"2019","journal-title":"Hypertens. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179035_bib106","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0028-3908(97)00086-5","article-title":"Contrasting biophysical and pharmacological properties of T-type and R-type calcium channels","volume":"36","author":"Randall","year":"1997","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib107","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41588-023-01498-5","article-title":"Somatic SLC30A1 mutations altering zinc transporter ZnT1 cause aldosterone-producing adenomas and primary aldosteronism","volume":"55","author":"Rege","year":"2023","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179035_bib108","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib109","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1530\/EJE-14-0444","article-title":"Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy","volume":"172","author":"Riester","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/hr.2016.85","article-title":"Dihydropyridine calcium channel blockers and renal disease","volume":"40","author":"Robles","year":"2017","journal-title":"Hypertens. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0039-128X(99)00087-2","article-title":"Mineralocorticoid action","volume":"65","author":"Rogerson","year":"2000","journal-title":"Steroids"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib112","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0b013e3282f4b3e6","article-title":"Primary aldosteronism: an update on screening, diagnosis and treatment","volume":"26","author":"Rossi","year":"2008","journal-title":"J. Hypertens."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib113","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.124.22642","article-title":"Clinical management of primary aldosteronism: an update","volume":"81","author":"Rossi","year":"2024","journal-title":"Hypertension"},{"issue":"3\u20134","key":"10.1016\/j.ejphar.2026.179035_bib114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ando.2020.02.006","article-title":"The cardiovascular consequences of hyperaldosteronism","volume":"82","author":"Rossi","year":"2021","journal-title":"Ann. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib115","doi-asserted-by":"crossref","first-page":"F391","DOI":"10.1152\/ajprenal.2001.281.3.F391","article-title":"Trafficking and cell surface stability of ENaC","volume":"281","author":"Rotin","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib116","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.surg.2018.05.085","article-title":"Keeping primary aldosteronism in mind: deficiencies in screening at-risk hypertensives","volume":"165","author":"Ruhle","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12020-021-02763-5","article-title":"A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy","volume":"74","author":"Sanga","year":"2021","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib118","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1161\/HYPERTENSIONAHA.121.16498","article-title":"Genetics of primary aldosteronism","volume":"79","author":"Scholl","year":"2022","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib119","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat. Genet."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179035_bib120","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1073\/pnas.1121407109","article-title":"Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5","volume":"109","author":"Scholl","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2026.179035_bib121","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06315","article-title":"Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism","volume":"4","author":"Scholl","year":"2015","journal-title":"eLife"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib122","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41588-018-0048-5","article-title":"CLCN2 chloride channel mutations in familial hyperaldosteronism type II","volume":"50","author":"Scholl","year":"2018","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179035_bib123","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00424-014-1668-y","article-title":"Salt feedback on the renin-angiotensin-aldosterone system","volume":"467","author":"Schweda","year":"2015","journal-title":"Pflugers Arch"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib124","first-page":"1029","article-title":"The biology of normal zona glomerulosa and aldosterone-producing adenoma: pathological implications","volume":"39","author":"Seccia","year":"2018","journal-title":"Endocr. Rev."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179035_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0337-9","article-title":"Genetic causes of primary aldosteronism","volume":"51","author":"Seidel","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"21","key":"10.1016\/j.ejphar.2026.179035_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112803","article-title":"YM750, an ACAT inhibitor, acts on adrenocortical cells to inhibit aldosterone secretion due to depolarization","volume":"23","author":"Shimada","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179035_bib127","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70000","article-title":"First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor","volume":"17","author":"Shimizu","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1152\/physrev.00030.2003","article-title":"Control of aldosterone secretion: a model for convergence in cellular signaling pathways","volume":"84","author":"Spat","year":"2004","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179035_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100191","article-title":"The role of lipid second messengers in aldosterone synthesis and secretion","volume":"63","author":"Spaulding","year":"2022","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/svn-2017-000138","article-title":"Controlling resistant hypertension","volume":"3","author":"Spence","year":"2018","journal-title":"Stroke Vasc Neurol"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib131","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1073\/pnas.090091297","article-title":"Uncompensated polyuria in a mouse model of Bartter's syndrome","volume":"97","author":"Takahashi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib132","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.3390\/ijms24065782","article-title":"Molecular and epigenetic control of aldosterone synthase, CYP11B2 and 11-Hydroxylase, CYP11B1","volume":"24","author":"Takeda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib133","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008281","article-title":"Epigenetic regulation of aldosterone synthase gene by sodium and angiotensin II","volume":"7","author":"Takeda","year":"2018","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib134","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.3390\/ijms22094587","article-title":"DNA methylation of the angiotensinogen gene, AGT, and the aldosterone synthase gene, CYP11B2 in cardiovascular diseases","volume":"22","author":"Takeda","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.amjhyper.2006.05.022","article-title":"Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride","volume":"20","author":"Teiwes","year":"2007","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib136","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/JOE-16-0237","article-title":"Very low-density lipoprotein (VLDL)-induced signals mediating aldosterone production","volume":"232","author":"Tsai","year":"2017","journal-title":"J. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib137","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMc2508629","article-title":"Phase 2a study of Baxdrostat in primary aldosteronism","volume":"393","author":"Turcu","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179035_bib138","doi-asserted-by":"crossref","first-page":"K50","DOI":"10.1093\/ejendo\/lvaf099","article-title":"Real-world outcomes of finerenone in primary aldosteronism","volume":"192","author":"Uslar","year":"2025","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib139","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/CS20171525","article-title":"Aldosterone, SGK1, and ion channels in the kidney","volume":"132","author":"Valinsky","year":"2018","journal-title":"Clin. Sci. (Lond.)"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib140","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/HYPERTENSIONAHA.125.24909","article-title":"Somatic mutations in MCOLN3 are associated with aldosterone-producing adenomas","volume":"82","author":"van Rooyen","year":"2025","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib141","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/HYPERTENSIONAHA.113.02303","article-title":"Dynamic CCAAT\/enhancer binding protein-associated changes of DNA methylation in the angiotensinogen gene","volume":"63","author":"Wang","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2026.179035_bib142","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fendo.2020.00260","article-title":"The effects of different calcium channel blockers on aldosterone-producing adenoma cells","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"14","key":"10.1016\/j.ejphar.2026.179035_bib143","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.gt.3302768","article-title":"AAV delivery of mineralocorticoid receptor shRNA prevents progression of cold-induced hypertension and attenuates renal damage","volume":"13","author":"Wang","year":"2006","journal-title":"Gene Ther."},{"issue":"1\u20136","key":"10.1016\/j.ejphar.2026.179035_bib144","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0960-0760(99)00071-0","article-title":"Aldosterone synthase (CYP11B2) polymorphisms and cardiovascular function","volume":"69","author":"White","year":"1999","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179035_bib145","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF03349762","article-title":"Glucocorticoid-remediable aldosteronism","volume":"18","author":"Williams","year":"1995","journal-title":"J. Endocrinol. Investig."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179035_bib146","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tem.2021.10.002","article-title":"Pathophysiology and histopathology of primary aldosteronism","volume":"33","author":"Williams","year":"2022","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib147","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.tem.2024.12.001","article-title":"Targeting cholesterol-dependent adrenal steroidogenesis for management of primary aldosteronism","volume":"36","author":"Wu","year":"2025","journal-title":"Trends Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib148","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41588-023-01403-0","article-title":"Somatic mutations of CADM1 in aldosterone-producing adenomas and gap junction-dependent regulation of aldosterone production","volume":"55","author":"Wu","year":"2023","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib149","doi-asserted-by":"crossref","first-page":"E531","DOI":"10.1152\/ajpendo.00022.2023","article-title":"Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"324","author":"Yao","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179035_bib150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41440-024-01970-7","article-title":"Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism","volume":"48","author":"Yoshida","year":"2025","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib151","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/HYPERTENSIONAHA.116.08313","article-title":"Hypomethylation of CYP11B2 in aldosterone-producing adenoma","volume":"68","author":"Yoshii","year":"2016","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib152","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jch.14877","article-title":"Primary aldosteronism with postoperative elevation of aldosterone treated effectively by finerenone: a case report","volume":"26","author":"Yu","year":"2024","journal-title":"J. Clin. Hypertens."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179035_bib153","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41574-020-0382-4","article-title":"Pathogenesis and treatment of primary aldosteronism","volume":"16","author":"Zennaro","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"14","key":"10.1016\/j.ejphar.2026.179035_bib154","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.7150\/ijbs.48437","article-title":"E3 Ubiquitin ligase NEDD4 family-regulatory network in cardiovascular disease","volume":"16","author":"Zhang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib155","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/oby.20716","article-title":"High-salt intake induced visceral adipose tissue hypoxia and its association with circulating monocyte subsets in humans","volume":"22","author":"Zhou","year":"2014","journal-title":"Obesity"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179035_bib156","first-page":"971","article-title":"Dilemmas and breakthroughs in primary aldosteronism treatment: from conventional therapies to target interventions","volume":"53","author":"Zhu","year":"2025","journal-title":"Zhonghua Xinxueguanbing Zazhi"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179035_bib157","doi-asserted-by":"crossref","first-page":"E900","DOI":"10.1210\/jc.2014-4167","article-title":"Primary aldosteronism and ARMC5 variants","volume":"100","author":"Zilbermint","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926005170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:13:53Z","timestamp":1784808833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926005170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":153,"alternative-id":["S0014299926005170"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179035","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the untargeted: Molecular insights and emerging therapeutic strategies for primary aldosteronism","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179035"}}